Literature DB >> 7932701

Amino acid requirements of the nucleocapsid protein of HIV-1 for increasing catalytic activity of a Ki-ras ribozyme in vitro.

G Müller1, B Strack, J Dannull, B S Sproat, A Surovoy, G Jung, K Moelling.   

Abstract

The nucleocapsid protein NCp7 of HIV-1 is a single-stranded nucleic acid binding protein with several functions such as specific recognition, dimerization and packaging of viral RNA, tRNA annealing to viral RNA and protection against nucleases. Since some of these functions involve annealing and double-stranded RNA-melting activity we applied the nucleocapsid protein to a hammerhead ribozyme specific for the activated Ki-ras mRNA in vitro, which carries at its mutated codon 12 a GUU site. A synthetic ribozyme containing 2'-O-allyl-modified nucleotides and alternatively in vitro transcribed ribozymes were used. At a one to one molar ratio of substrate to ribozyme almost no cleavage is observed at 37 degrees C. Presence of a synthetic nucleocapsid protein significantly increases the catalytic activity of the ribozyme. Kinetic analyses by means of single and multiple turnover reactions performed at various substrate to ribozyme ratios lead to only a slight stimulation of the rate constants for single turnover reactions. The rate constants in multiple turnover reactions, however, are stimulated up to 17-fold by the presence of the nucleocapsid protein. The activating region of the nucleocapsid protein was characterized by a number of mutants. The mutants demonstrate that activation requires both basic amino acid clusters as evidenced by point mutations. Deletion mutants indicate that the second zinc finger is totally dispensable and that replacement of the first zinc finger by a glycine-glycine spacer only slightly reduces the enhancing effect of the nucleocapsid protein on the ribozyme.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7932701     DOI: 10.1006/jmbi.1994.1592

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  15 in total

1.  Rapid kinetic characterization of hammerhead ribozymes by real-time monitoring of fluorescence resonance energy transfer (FRET).

Authors:  K K Singh; R Parwaresch; G Krupp
Journal:  RNA       Date:  1999-10       Impact factor: 4.942

2.  Specificity of hammerhead ribozyme cleavage.

Authors:  K J Hertel; D Herschlag; O C Uhlenbeck
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

3.  Peptide nucleic acid (PNA) is capable of enhancing hammerhead ribozyme activity with long but not with short RNA substrates.

Authors:  E Jankowsky; G Strunk; B Schwenzer
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

4.  Are viruses our oldest ancestors?

Authors:  Karin Moelling
Journal:  EMBO Rep       Date:  2012-11-13       Impact factor: 8.807

5.  Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA.

Authors:  J Guo; L E Henderson; J Bess; B Kane; J G Levin
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Molecular requirements for human immunodeficiency virus type 1 plus-strand transfer: analysis in reconstituted and endogenous reverse transcription systems.

Authors:  T Wu; J Guo; J Bess; L E Henderson; J G Levin
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

7.  HIV-1 nucleocapsid protein induces "maturation" of dimeric retroviral RNA in vitro.

Authors:  Y X Feng; T D Copeland; L E Henderson; R J Gorelick; W J Bosche; J G Levin; A Rein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

8.  Mutations of basic amino acids of NCp7 of human immunodeficiency virus type 1 affect RNA binding in vitro.

Authors:  E Schmalzbauer; B Strack; J Dannull; S Guehmann; K Moelling
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Actinomycin D inhibits human immunodeficiency virus type 1 minus-strand transfer in in vitro and endogenous reverse transcriptase assays.

Authors:  J Guo; T Wu; J Bess; L E Henderson; J G Levin
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  Oligonucleotide facilitators may inhibit or activate a hammerhead ribozyme.

Authors:  E Jankowsky; B Schwenzer
Journal:  Nucleic Acids Res       Date:  1996-02-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.